Hosted on MSN2d
SpringWorks Therapeutics (SWTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseWall Street expects a year-over-year increase in earnings on higher revenues when SpringWorks Therapeutics (SWTX) reports results for the quarter ended December 2024. While this widely-known consensus ...
We recently compiled a list of the 10 Firms Begin Trading Week With Impressive Gains. In this article, we are going to take a ...
SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved Gomekli, a small molecule MEK inhibitor, ...
BofA raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $87 from $65 and keeps a Buy rating on the shares. Shares gained a ...
SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...
$SWTX insiders have traded $SWTX stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales. We have seen ...
The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...
Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...
SpringWorks Therapeutics ( NASDAQ: SWTX) soared ~40% after a report that Merck KGaA ( OTCPK:MKGAF) is in advanced discussions ...
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report)’s share price gapped up prior to trading on Wednesday after Evercore ISI raised their price target on the stock from $60.00 to $ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback